Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2213–2214. doi: 10.1128/aac.38.9.2213

In vitro activity of dirithromycin against Chlamydia trachomatis.

J Segreti 1, K S Kapell 1
PMCID: PMC284716  PMID: 7811051

Abstract

Dirithromycin is a new macrolide antibiotic with an active metabolite, erythromycylamine. We evaluated the in vitro activities of both drugs against 16 isolates of Chlamydia trachomatis and compared them with that of doxycycline. In vitro susceptibility testing was performed with McCoy cell monolayers. The MIC was defined as the lowest concentration of antibiotic without inclusions. The MBC was defined as the lowest concentration of antibiotic yielding no inclusions after passage onto 24-h-old antibiotic-free McCoy cell monolayers. Dirithromycin and erythromycylamine appeared to be equally effective against these 16 strains of C. trachomatis (MIC for 90% of strains tested, 1 mg/ml; MBC for 90% of strains tested, 2 micrograms/ml). Both were less active than doxycycline (MIC for 90% of strains tested, 0.06 micrograms/ml; MBC for 90% of strains tested, 0.12 micrograms/ml). The combination of dirithromycin and erythromycylamine appeared to be additive.

Full text

PDF
2213

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bowie W. R., Shaw C. E., Chan D. G., Black W. A. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 Mar;31(3):470–472. doi: 10.1128/aac.31.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1413–1418. doi: 10.1128/aac.33.9.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Robson H. G., Shah P. P., Lalonde R. G., Hayes L., Senikas V. M. Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis. Sex Transm Dis. 1983 Jul-Sep;10(3):130–134. doi: 10.1097/00007435-198307000-00006. [DOI] [PubMed] [Google Scholar]
  5. Scieux C., Bianchi A., Chappey B., Vassias I., Pérol Y. In-vitro activity of azithromycin against Chlamydia trachomatis. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):7–10. doi: 10.1093/jac/25.suppl_a.7. [DOI] [PubMed] [Google Scholar]
  6. Segreti J., Kessler H. A., Kapell K. S., Trenholme G. M. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 Jan;31(1):100–101. doi: 10.1128/aac.31.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Walsh M., Kappus E. W., Quinn T. C. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987 May;31(5):811–812. doi: 10.1128/aac.31.5.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Washington A. E., Johnson R. E., Sanders L. L., Jr Chlamydia trachomatis infections in the United States. What are they costing us? JAMA. 1987 Apr 17;257(15):2070–2072. [PubMed] [Google Scholar]
  9. Yu K. W., Neu H. C. In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics. Antimicrob Agents Chemother. 1990 Sep;34(9):1839–1842. doi: 10.1128/aac.34.9.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES